Biogen files reply in support of dismissing product-hopping claims in US pharma case
MLex Summary: Biogen filed a reply in support of dismissing US antitrust claims accusing it of coercing patients into switching from Tecfidera, which is used to treat multiple sclerosis, to the new drug Vumerity,...To view the full article, register now.
Already a subscriber? Click here to view full article